

IL29

Recombinant Human Interleukin-29/IFN-lambda 1

Catalog No.	CRI010A CRI010B CRI010C	Quantity:	5 µg 20 µg 1.0 mg
Alternate Names:	Interferon lambda-1, Interleukin-29, IL29, IFNL1, IFN-lambda-1, IL-29		
Description:	<p>IL-28A, IL-28B, and IL-29, also named interferon-λ2 (IFN-λ2), IFN-λ3, and IFN-λ1, respectively, are newly identified class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11-13% aa sequence identity) and the type I IFN family (15-19% aa sequence identity). The expression of IL-28A, B, and IL-29 is induced by virus infection or doublestranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and upregulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor β (IL-10 Rβ) and a novel IL-28 receptor α (IL-28 Rα, also known as IFN-λR1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation.</p> <p>Recombinant Human IL-29/IFN-lambda 1 is a single non-glycosylated polypeptide chain containing 181 amino acids.</p>		
Gene ID:	282618		
Source:	<i>E. coli</i>		
Molecular Weight:	19.8 kDa		
Formulation:	Lyophilized from a 0.2 µm filtered concentrated solution in 20 mM PB, pH 7.4 + 130 mM NaCl.		
Purity:	>97% by SDS-PAGE and HPLC analyses.		
Endotoxin Level:	Less than 1EU/µg as determined by LAL method.		
Biological Activity:	Fully biologically active. The ED ₅₀ determined by an anti-viral assay using human HepG2 cells infected with encephalomyocarditis is less than 5 ng/ml		
Specific Activity:	> 2.0 × 10 ⁵ IU/mg.		
Amino Acid Sequence:	GPVPTSKPTT TGKGCHIGRF KSLSPQELAS FKKARDALEE SLKLNWSCS SPVFPGNWDL RLLQVRERPV ALEAELALTL KVLEAAAGPA LEDVLDQPLH TLHHLSQLQ ACIQPQPTAG PRPRGRLHHW LHRLQEAPKK ESAGCLEASV TFNLFRLLTR DLKYVADGNL CLRTSTHPES T		
Reconstitution:	Centrifuge vial prior to opening. Add sterile distilled water or aqueous buffer to a concentration of 0.1-1.0 mg/mL. Further dilutions should be made in appropriate buffered solutions.		
Storage & Stability:	This lyophilized preparation is stable at 2-8°C, but should be kept desiccated at -20°C for long term storage. Upon reconstitution, the preparation is stable for up to one week at 2-8°C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20°C to -80°C. Avoid repeated freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.